+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Oral 1,25-dihydroxyvitamin D3 minipulse therapy

Oral 1,25-dihydroxyvitamin D3 minipulse therapy

Nephron 67(1): 121-122

(PDF 0-2 workdays service: $29.90)

Accession: 032655751

Download citation: RISBibTeXText

PMID: 8052357

Related references

Oral minipulse therapy in vitiligo. Dermatology 190(3): 251-252, 1995

Randomized controlled study to evaluate the effectiveness of dexamethasone oral minipulse therapy versus oral minocycline in patients with active vitiligo vulgaris. Indian Journal of Dermatology, Venereology and Leprology 80(1): 29-35, 2016

A Comparative Study of Oral Cyclosporine and Betamethasone Minipulse Therapy in the Treatment of Alopecia Areata. Annals of Dermatology 28(5): 569-574, 2016

Relapse after methylprednisolone oral minipulse therapy in childhood vitiligo: a 12-month follow-up study. Indian Journal of Dermatology 58(2): 113-116, 2013

Childhood vitiligo: response to methylprednisolone oral minipulse therapy and topical fluticasone combination. Indian Journal of Dermatology 54(2): 124-127, 2010

Bullous Lichen Planus treated with Oral Minipulse Therapy: A Rare Case Report. Journal of Clinical and Diagnostic Research 8(12): Zd17-Zd19, 2015

A Randomized Comparative Study of Oral Corticosteroid Minipulse and Low-Dose Oral Methotrexate in the Treatment of Unstable Vitiligo. Dermatology 231(3): 286-290, 2016

An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad / narrow band UVB phototherapy in progressive vitiligo. Indian Journal of Dermatology, Venereology and Leprology 74(4): 357-360, 2008

Therapy of secondary hyperparathyrodism with intermittent oral bolus of 1,25 dihydroxyvitamin D3. Bone (New York) 14(1): 76, 1993

Effect of oral 1,25 dihydroxyvitamin D-3 pulse therapy on secondary hyperparathyroidism. Nichidai Igaku Zasshi 51(8): 801-806, 1992

Can oral 1 25 dihydroxyvitamin d 3 pulse therapy reduce parathyroid hyperplasia. Nephron 59(1): 171-172, 1991

Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy. Mineral and Electrolyte Metabolism 21(1-3): 223-228, 1995

Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy. Journal of Bone and Mineral Research 10(4): 594-600, 1995

A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3. Nihon Jinzo Gakkai Shi 31(4): 393-401, 1989

Comparisons between oral and intraperitoneal 1,25-dihydroxyvitamin D3 therapy in children treated with peritoneal dialysis. Clinical Nephrology 42(1): 44-49, 1994